Provided by Tiger Fintech (Singapore) Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.7456
-0.0368-4.70%
Post-market: 0.74560.00000.00%19:53 EDT
Volume:424.14K
Turnover:321.06K
Market Cap:34.85M
PE:-0.83
High:0.8000
Open:0.7900
Low:0.7207
Close:0.7824
Loading ...

Company Profile

Company Name:
Reviva Pharmaceuticals Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
14
Office Location:
10080 N. Wolfe Road,Suite SW3-200,Cupertino,California,United States
Zip Code:
95014
Fax:
408 904 6270
Introduction:
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

Directors

Name
Position
Laxminarayan Bhat
President, Chief Executive Officer, Director
Parag Saxena
Chairman of the Board
Les Funtleyder
Director
Purav Patel
Director
Richard Margolin
Director

Shareholders

Name
Position
Laxminarayan Bhat
President, Chief Executive Officer, Director
Narayan Prabhu
Chief Financial Officer